Please assess the completion status of the following clinical trial:

Trial Title: Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient (male or female) has histologically proven, measurable metastatic cutaneous melanoma in one of the following stages according to the American Joint Committee on Cancer classification of 2002:~   * Stage III in transit, or~  * Stage III unresectable, or~  * Stage IV M1a.~2. There has been documented progression of the patient's disease within the 12 weeks before the first administration of study treatment.~3. The patient presents at screening with at least 3 tumor lesions of diameter \>= 0.5 mm.~4. Written informed consent has been obtained from the patient before the performance of any protocol-specific procedure.~5. The patient is \>= 18 years of age at the time of signature of informed consent.~6. The patient's tumor shows expression of MAGE-A3 gene in at least one of the two tumor biopsies performed at baseline.~7. The patient's ECOG performance status is 0 or 1.~8. The patient has normal organ functions, as assessed by standard laboratory criteria.~9. If the patient is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during the entire study treatment period and for 2 months after completion of the treatment injection series.~10. In the view of the investigator, the patient can and will comply with the requirements of the protocol.~Exclusion Criteria:~1. The patient has at any time received systemic (bio)-chemotherapy~2. The patient is scheduled to receive any anti-cancer specific treatment, including radiotherapy, immunotherapy, chemotherapy and immunomodulating agents.~3. The patient requires concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents.~4. The patient has received any cancer immunotherapeutic containing a MAGE A3 antigen or any cancer immunotherapeutic for his/her metastatic disease.~5. Use of any investigational or non-registered product (drug or vaccine) other than the study treatment within the 30 days preceding the first dose of study treatment, or planned use during the study period.~6. The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.~7. History of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.~8. The patient has an autoimmune disease such as, but not limited to, neuroinflammatory autoimmune diseases, systemic lupus erythematosus, and inflammatory bowel disease~9. The patient has a family history of congenital or hereditary immunodeficiency.~10. The patient is known to be positive for the human immunodeficiency virus (HIV).~11. The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the study procedures.~12. The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.~13. For female patients: the patient is pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK2132231A Group (Type: EXPERIMENTAL): Subjects, male or female, 18 years of age or older, received up to 24 doses of GSK2132231A intramuscularly in 4 cycles. In Cycle 1 (ending Week 13) 6 doses were administered at 2-week intervals; in Cycle 2 (ending Week 32) 6 doses at 3-week intervals; in Cycle 3 (ending Week 54) 4 doses at 6-week intervals and in Cycle 4 4 doses at 12-week intervals, starting 12 weeks after end of Cycle 3, followed by, after an interruption of treatment of 6 months, 4 doses at 24-week intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).